Shop by Product Category
Purchase Assistance
Join Mail List

We Accept: 
Catalog

Product Catalog# Quantity Unit Price Buy
Neu (C18) Antibody DB049 0.200 mg/ml $190.00

Datasheet 
Datasheet 

For technical service please call (800) 595 1994
Product Info
Background The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3). 
Origin Neu (C18) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). 
Product Details Each vial contains 200 g/ml of affinity purified rabbit IgG Neu (C18) DB049, in 1 ml PBS containing 0.1% sodium azide and 0.2% gelatin. 
Competition Studies A blocking peptide is also available, DB049P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 mg BSA. 
Form 200 g/ml of rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin. 
Immunogen Synthetic peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). 
Specificity Neu (C18) DB049 reacts with Neu of mouse, rat, and human origin by western blotting, immunoprecipitation, and immunohistochemistry (including paraffin-embedded sections). Western blotting starting dilution: 1:200. SK-BR-3 lysates can be used as a positive control. 
Use
Western blot analysis of Neu expression in SK-BR-3 whole cell lysates. 
Storage Store this product at 4 C, do not freeze. The product is stable for one year from the date of shipment. 
References 1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7
 

For Technical service please call +1-800-595-1994
Delta Biolabs+1-408-846-6650 • fax:+1-408-846-6645 • Copyright © 2001.Allrights reserved.
Powered by Corezon





Apoptosis/Tumor Suppressor Genes| Cell Adhesion| Cell Cycle| Controls| Fusion Protein/Epitope Tags| Growth Factors| Membrane Receptors
Protein Kinases| Secondary Antibodies| Signaling Intermediates| Transcription Regulation